Concizumab prophylaxis significantly reduces bleeding events for people with hemophilia
Prophylactic concizumab conferred significant reductions in treated spontaneous and traumatic bleeds among patients with hemophilia A or B without inhibitors, a primary analysis of the randomized phase 3 explorer8 study showed.Concizumab (Novo Nordisk) prophylaxis reduced the number of bleeds by 86% for trial participants with hemophilia A and by 79% for participants with hemophilia B compared
Source: healio.com
![Market cap of Borqs Technologies Inc. [BRQS] reaches 67.79M – now what? - Vimarsana News](https://dbtnews.com/wp-content/uploads/2020/01/Image-19.png)